Argenx looks for quick label expansion for subcutaneous Vyvgart with PhII data — shares soar
Less than a month after argenx first landed approval of the subcutaneous version of its top drug, the Dutch biotech has notched another win in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
